Interested in specific Information?

Filter what you see here

General MM

Quick poll

Association of subclonal TP53 deletions with multiple myeloma…

Association of subclonal TP53 deletions with multiple myeloma prognosis

Closes Nov 14, 2018

Patients eligible for transplant

Quick poll

Long-term results from the HOVON-50 trial on the use of thalidomide for…

Closes Nov 8, 2018

Relapsed/refractory patients

Quick poll

FDA approves elotuzumab in combination with pomalidomide and dexamethasone…

Closes Nov 8, 2018 , Expert Opinion

General MM

Quick poll

ESH MM 2018 | Assessment of response in multiple myeloma

ESH MM 2018 | Assessment of response in multiple myeloma

Closes Nov 1, 2018

Patients eligible for transplant,   Patients non-eligible for transplant

Quick poll

ESH MM 2018 | Continuous or fixed-duration therapy in multiple myeloma?

Closes Oct 30, 2018

Patients eligible for transplant,   Patients non-eligible for transplant

Quick poll

ESH MM 2018 | How to treat newly diagnosed multiple myeloma

Closes Oct 29, 2018

Relapsed/refractory patients

Quick poll

FDA grants Orphan Drug Designation to STRO-001 for the treatment of…

FDA grants Orphan Drug Designation to STRO-001 for the treatment of multiple myeloma

Closes Oct 17, 2018

General MM

Quick poll

Supportive care: managing infection in myeloma | An interview with Heinz…

Closes Oct 12, 2018

General MM

Quick poll

Robert Hills | ESH MM 2018 | How to judge the value of a clinical trial

Closes Oct 9, 2018

Relapsed/refractory patients

Quick poll

Selinexor granted FDA priority review

Selinexor granted FDA priority review

Closes Oct 9, 2018

General MM

Quick poll

Kenneth Anderson | ESH MM 2018 | Future combinations for the treatment of…

Closes Oct 8, 2018

General MM

Quick poll

Herve Avet-Loiseau | ESH MM 2018 | Genetics and risk assessment

Closes Oct 8, 2018

General MM

Quick poll

Shaji Kumar | ESH MM 2018 | New end-points and new design for clinical…

Shaji Kumar | ESH MM 2018 | New end-points and new design for clinical trials

Closes Oct 8, 2018

General MM

Quick poll

Saad Usmani | ESH MM 2018 | Progress in MM with monoclonal antibodies

Closes Oct 7, 2018

General MM

Quick poll

Jesus Berdeja | ESH MM 2018 | Adoptive cell therapy

Closes Oct 7, 2018
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Congress Coverage

Latest Biology

Latest Drug Updates

Relapsed/refractory patients

FDA approves elotuzumab in combination with pomalidomide and dexamethasone for…

Nov 8, 2018 , Expert Opinion
Relapsed/refractory patients

Selinexor granted FDA priority review

Oct 9, 2018

Recently updated Licenses

Where we are next

60th ASH Annual Meeting & Exposition

December 1–4, 2018 | San Diego, CA

The meeting prides itself on bringing together professionals worldwide to highlight 'state-of-the-art clinical practice and the latest findings in hematology research'. The program covers all hematological indications, including multiple myeloma. Stay tuned to follow our first-hand ASH coverage.

#ASH18 #mmsm 

Event Website

Map Data
Map data ©2018 Google
Map DataMap data ©2018 Google
Map data ©2018 Google

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology